文献速递脊柱关节炎

临床应答标准与疾病活动度水平同中轴型脊柱关节炎核心领域的关联:BE MOBILE 1与2两项3期随机研究结果

Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2.
PubMed 文献 · RMD Open · 2024-04-10

研究汇总BE MOBILE 1和2两项3期随机研究中52周时达到不同临床应答标准或疾病活动度状态的患者,评估其与核心领域患者报告结局改善幅度的关联。结果显示,达到越严格临床应答标准的患者,在疼痛、疲劳、躯体功能、整体功能与健康及工作就业等核心领域的改善幅度越大;放射学阴性中轴型脊柱关节炎(nr-axSpA)与放射学阳性中轴型脊柱关节炎(r-axSpA)患者改善幅度相似。

要点

  • 52周时达到越严格临床应答标准或越低疾病活动度,核心领域患者报告结局改善越大。
  • nr-axSpA中达到ASAS40者较仅达ASAS20未达ASAS40者,总脊柱疼痛改善-5.3 vs -2.8。
  • nr-axSpA与r-axSpA患者改善幅度相似。

核心结论

  • 接受比美吉珠单抗治疗的全中轴型脊柱关节炎疾病谱患者,52周时达到越严格临床应答标准和越低疾病活动度者,其核心中轴型脊柱关节炎领域改善幅度越大。

研究设计与样本

  • 研究汇总BE MOBILE 1和2两项3期随机研究中第52周达到不同应答水平或疾病活动度状态的患者,不考虑治疗分组。
  • 评估达到这些终点与基线以来核心中轴型脊柱关节炎领域患者报告结局变化之间的关联,领域包括疼痛、疲劳、躯体功能、整体功能与健康及工作就业。

主要发现

  • nr-axSpA中达到ASAS40者较未达ASAS40但达ASAS20者,总脊柱疼痛变化-5.3 vs -2.8。
  • nr-axSpA中达到ASAS40者较未达ASAS40但达ASAS20者,慢性病治疗功能评估-疲劳子量表变化12.7 vs 6.7。
  • nr-axSpA中达到ASAS40者较未达ASAS40但达ASAS20者,Bath强直性脊柱炎功能指数变化-3.9 vs -1.8。
  • nr-axSpA中达到ASAS40者较未达ASAS40但达ASAS20者,欧洲五维健康量表3级版本变化0.30 vs 0.16。
  • nr-axSpA中达到ASAS40者较未达ASAS40但达ASAS20者,工作生产力与活动受损-中轴型脊柱关节炎出勤主义变化-35.4 vs -15.9,整体工作受损-36.5 vs -12.9,活动受损-39.0 vs -21.0,睡眠变化9.0 vs 3.9。

关键数值与推荐

  • ASDAS和BASDAI50应答标准的结果与ASAS40类似。
  • nr-axSpA与r-axSpA患者之间观察到相似幅度的改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess how achievement of increasingly stringent clinical response criteria and disease activity states at week 52 translate into changes in core domains in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA). METHODS: Patients in BE MOBILE 1 and 2 achieving different levels of response or disease activity (Assessment of SpondyloArthritis International Society (ASAS) and Ankylosing Spondylitis Disease Activity Score (ASDAS) response criteria, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50)) at week 52 were pooled, regardless of treatment arm. Associations between achievement of these endpoints and change from baseline (CfB) in patient-reported outcomes (PROs) measuring core axSpA domains, including pain, fatigue, physical function, overall functioning and health, and work and employment, were assessed. RESULTS: Achievement of increasingly stringent clinical efficacy endpoints at week 52 was generally associated with sequentially greater improvements from baseline in all PROs. Patients with nr-axSpA achieving ASAS40 demonstrated greater improvements (CfB) than patients who did not achieve ASAS40 but did achieve ASAS20, in total spinal pain (-5.3 vs -2.8, respectively), Functional Assessment of Chronic Illness-Fatigue subscale (12.7 vs 6.7), Bath Ankylosing Spondylitis Function Index (-3.9 vs -1.8), European Quality of Life 5-Dimension 3-Level Version (0.30 vs 0.16), Work Productivity and Activity Impairment-axSpA presenteeism (-35.4 vs -15.9), overall work impairment (-36.5 vs -12.9), activity impairment (-39.0 vs -21.0) and sleep (9.0 vs 3.9). Results were similar for ASDAS and BASDAI50. Similar amplitudes of improvement were observed between patients with nr-axSpA and r-axSpA. CONCLUSIONS: Patients treated with bimekizumab across the full axSpA disease spectrum, who achieved increasingly stringent clinical response criteria and lower disease activity at week 52, reported larger improvements in core axSpA domains.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Navarro-Compán V, Ramiro S, Deodhar A, et al. Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD Open. 2024. PMID: 38599650. doi:10.1136/rmdopen-2023-004040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。